Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency

Divya Punwani, Misako Kawahara, Jason Yu, Ukina Sanford, Sushmita Roy, Kiran Patel, Denise A. Carbonaro, Andrea D. Karlen, Sara Khan, Kenneth Cornetta, Michael Rothe, Axel Schambach, Donald B. Kohn, Harry L. Malech, R. Scott McIvor, Jennifer M. Puck, Morton J. Cowan

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

During B and T lymphocyte maturation, V(D)J recombination is initiated by creation of DNA doublestrand breaks. Artemis is an exonuclease essential for their subsequent repair by nonhomologous end-joining. Mutations in DCLRE1C, the gene encoding Artemis, cause T-B-NK+ severe combined immunodeficiency (ART-SCID) and also confer heightened sensitivity to ionizing radiation and alkylating chemotherapy. Although allogeneic hematopoietic cell transplantation can treat ART-SCID, conditioning regimens are poorly tolerated, leading to early mortality and/or late complications, including short stature, endocrinopathies, and dental aplasia. However, without alkylating chemotherapy as preconditioning, patients usually have graft rejection or limited T cell and no B cell recovery. Thus, addition of normal DCLRE1C cDNA to autologous hematopoietic stem cells is an attractive strategy to treat ART-SCID. We designed a self-inactivating lentivirus vector containing human Artemis cDNA under transcriptional regulation of the human endogenous Artemis promoter (AProArt). Fibroblasts from ART-SCID patients transduced with AProArt lentivirus showed correction of radiosensitivity. Mobilized peripheral blood CD34+ cells from an ART-SCID patient as well as hematopoietic stem cells from Artemis-deficient mice demonstrated restored T and B cell development following AProArt transduction. Murine hematopoietic cells transduced with AProArt exhibited no increase in replating potential in an in vitro immortalization assay, and analysis of AProArt lentivirus insertions showed no predilection for sites that could activate oncogenes. These efficacy and safety findings support institution of a clinical trial of gene addition therapy for ART-SCID.

Original languageEnglish (US)
Pages (from-to)112-124
Number of pages13
JournalHuman gene therapy
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Severe Combined Immunodeficiency
Lentivirus
B-Lymphocytes
Hematopoietic Stem Cells
T-Lymphocytes
Complementary DNA
V(D)J Recombination
Drug Therapy
Exonucleases
DNA Breaks
Radiation Tolerance
Cell Transplantation
Graft Rejection
Ionizing Radiation
Oncogenes
Genetic Therapy
Blood Cells
Tooth
Fibroblasts
Clinical Trials

Keywords

  • Artemis
  • Gene therapy
  • Lentivirus
  • Radiation sensitivity
  • Severe combined immunodeficiency

Cite this

Punwani, D., Kawahara, M., Yu, J., Sanford, U., Roy, S., Patel, K., ... Cowan, M. J. (2017). Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency. Human gene therapy, 28(1), 112-124. https://doi.org/10.1089/hum.2016.064

Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency. / Punwani, Divya; Kawahara, Misako; Yu, Jason; Sanford, Ukina; Roy, Sushmita; Patel, Kiran; Carbonaro, Denise A.; Karlen, Andrea D.; Khan, Sara; Cornetta, Kenneth; Rothe, Michael; Schambach, Axel; Kohn, Donald B.; Malech, Harry L.; McIvor, R. Scott; Puck, Jennifer M.; Cowan, Morton J.

In: Human gene therapy, Vol. 28, No. 1, 01.01.2017, p. 112-124.

Research output: Contribution to journalArticle

Punwani, D, Kawahara, M, Yu, J, Sanford, U, Roy, S, Patel, K, Carbonaro, DA, Karlen, AD, Khan, S, Cornetta, K, Rothe, M, Schambach, A, Kohn, DB, Malech, HL, McIvor, RS, Puck, JM & Cowan, MJ 2017, 'Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency' Human gene therapy, vol. 28, no. 1, pp. 112-124. https://doi.org/10.1089/hum.2016.064
Punwani D, Kawahara M, Yu J, Sanford U, Roy S, Patel K et al. Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency. Human gene therapy. 2017 Jan 1;28(1):112-124. https://doi.org/10.1089/hum.2016.064
Punwani, Divya ; Kawahara, Misako ; Yu, Jason ; Sanford, Ukina ; Roy, Sushmita ; Patel, Kiran ; Carbonaro, Denise A. ; Karlen, Andrea D. ; Khan, Sara ; Cornetta, Kenneth ; Rothe, Michael ; Schambach, Axel ; Kohn, Donald B. ; Malech, Harry L. ; McIvor, R. Scott ; Puck, Jennifer M. ; Cowan, Morton J. / Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency. In: Human gene therapy. 2017 ; Vol. 28, No. 1. pp. 112-124.
@article{c1fa39544d5744c68a234aab17666bdb,
title = "Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency",
abstract = "During B and T lymphocyte maturation, V(D)J recombination is initiated by creation of DNA doublestrand breaks. Artemis is an exonuclease essential for their subsequent repair by nonhomologous end-joining. Mutations in DCLRE1C, the gene encoding Artemis, cause T-B-NK+ severe combined immunodeficiency (ART-SCID) and also confer heightened sensitivity to ionizing radiation and alkylating chemotherapy. Although allogeneic hematopoietic cell transplantation can treat ART-SCID, conditioning regimens are poorly tolerated, leading to early mortality and/or late complications, including short stature, endocrinopathies, and dental aplasia. However, without alkylating chemotherapy as preconditioning, patients usually have graft rejection or limited T cell and no B cell recovery. Thus, addition of normal DCLRE1C cDNA to autologous hematopoietic stem cells is an attractive strategy to treat ART-SCID. We designed a self-inactivating lentivirus vector containing human Artemis cDNA under transcriptional regulation of the human endogenous Artemis promoter (AProArt). Fibroblasts from ART-SCID patients transduced with AProArt lentivirus showed correction of radiosensitivity. Mobilized peripheral blood CD34+ cells from an ART-SCID patient as well as hematopoietic stem cells from Artemis-deficient mice demonstrated restored T and B cell development following AProArt transduction. Murine hematopoietic cells transduced with AProArt exhibited no increase in replating potential in an in vitro immortalization assay, and analysis of AProArt lentivirus insertions showed no predilection for sites that could activate oncogenes. These efficacy and safety findings support institution of a clinical trial of gene addition therapy for ART-SCID.",
keywords = "Artemis, Gene therapy, Lentivirus, Radiation sensitivity, Severe combined immunodeficiency",
author = "Divya Punwani and Misako Kawahara and Jason Yu and Ukina Sanford and Sushmita Roy and Kiran Patel and Carbonaro, {Denise A.} and Karlen, {Andrea D.} and Sara Khan and Kenneth Cornetta and Michael Rothe and Axel Schambach and Kohn, {Donald B.} and Malech, {Harry L.} and McIvor, {R. Scott} and Puck, {Jennifer M.} and Cowan, {Morton J.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1089/hum.2016.064",
language = "English (US)",
volume = "28",
pages = "112--124",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Lentivirus mediated correction of artemis-deficient severe combined immunodeficiency

AU - Punwani, Divya

AU - Kawahara, Misako

AU - Yu, Jason

AU - Sanford, Ukina

AU - Roy, Sushmita

AU - Patel, Kiran

AU - Carbonaro, Denise A.

AU - Karlen, Andrea D.

AU - Khan, Sara

AU - Cornetta, Kenneth

AU - Rothe, Michael

AU - Schambach, Axel

AU - Kohn, Donald B.

AU - Malech, Harry L.

AU - McIvor, R. Scott

AU - Puck, Jennifer M.

AU - Cowan, Morton J.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - During B and T lymphocyte maturation, V(D)J recombination is initiated by creation of DNA doublestrand breaks. Artemis is an exonuclease essential for their subsequent repair by nonhomologous end-joining. Mutations in DCLRE1C, the gene encoding Artemis, cause T-B-NK+ severe combined immunodeficiency (ART-SCID) and also confer heightened sensitivity to ionizing radiation and alkylating chemotherapy. Although allogeneic hematopoietic cell transplantation can treat ART-SCID, conditioning regimens are poorly tolerated, leading to early mortality and/or late complications, including short stature, endocrinopathies, and dental aplasia. However, without alkylating chemotherapy as preconditioning, patients usually have graft rejection or limited T cell and no B cell recovery. Thus, addition of normal DCLRE1C cDNA to autologous hematopoietic stem cells is an attractive strategy to treat ART-SCID. We designed a self-inactivating lentivirus vector containing human Artemis cDNA under transcriptional regulation of the human endogenous Artemis promoter (AProArt). Fibroblasts from ART-SCID patients transduced with AProArt lentivirus showed correction of radiosensitivity. Mobilized peripheral blood CD34+ cells from an ART-SCID patient as well as hematopoietic stem cells from Artemis-deficient mice demonstrated restored T and B cell development following AProArt transduction. Murine hematopoietic cells transduced with AProArt exhibited no increase in replating potential in an in vitro immortalization assay, and analysis of AProArt lentivirus insertions showed no predilection for sites that could activate oncogenes. These efficacy and safety findings support institution of a clinical trial of gene addition therapy for ART-SCID.

AB - During B and T lymphocyte maturation, V(D)J recombination is initiated by creation of DNA doublestrand breaks. Artemis is an exonuclease essential for their subsequent repair by nonhomologous end-joining. Mutations in DCLRE1C, the gene encoding Artemis, cause T-B-NK+ severe combined immunodeficiency (ART-SCID) and also confer heightened sensitivity to ionizing radiation and alkylating chemotherapy. Although allogeneic hematopoietic cell transplantation can treat ART-SCID, conditioning regimens are poorly tolerated, leading to early mortality and/or late complications, including short stature, endocrinopathies, and dental aplasia. However, without alkylating chemotherapy as preconditioning, patients usually have graft rejection or limited T cell and no B cell recovery. Thus, addition of normal DCLRE1C cDNA to autologous hematopoietic stem cells is an attractive strategy to treat ART-SCID. We designed a self-inactivating lentivirus vector containing human Artemis cDNA under transcriptional regulation of the human endogenous Artemis promoter (AProArt). Fibroblasts from ART-SCID patients transduced with AProArt lentivirus showed correction of radiosensitivity. Mobilized peripheral blood CD34+ cells from an ART-SCID patient as well as hematopoietic stem cells from Artemis-deficient mice demonstrated restored T and B cell development following AProArt transduction. Murine hematopoietic cells transduced with AProArt exhibited no increase in replating potential in an in vitro immortalization assay, and analysis of AProArt lentivirus insertions showed no predilection for sites that could activate oncogenes. These efficacy and safety findings support institution of a clinical trial of gene addition therapy for ART-SCID.

KW - Artemis

KW - Gene therapy

KW - Lentivirus

KW - Radiation sensitivity

KW - Severe combined immunodeficiency

UR - http://www.scopus.com/inward/record.url?scp=85009964387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009964387&partnerID=8YFLogxK

U2 - 10.1089/hum.2016.064

DO - 10.1089/hum.2016.064

M3 - Article

VL - 28

SP - 112

EP - 124

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -